Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
MaxCyte flags lower 2023 revenue, flat 2024 growth
(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022. The AIM-traded firm said core revenue was expected to fall between $29.6m and $29.8m, compared to $39.6m a year earlier, while strategic platform licence (SPL) programme-related revenue was anticipated to reach $11.4m, up from $4.6m.
It said it expected to have $210m in cash, cash equivalents and investments as of 31 December.
Looking ahead to 2024, MaxCyte's projected flat to 5% growth in core revenue compared to 2023 figures.
SPL programme-related revenue for the year was expected to be $3m.
That outlook notably excluded SPL programme-related revenue from the sale of Vertex and CRISPR's 'CASGEVY'.
MaxCyte said it expected to end 2024 with $175m in total cash, cash equivalents, and investments.
Maher Masoud, president and chief executive of MaxCyte, was upbeat about the company's trajectory.
"This year, MaxCyte has already signed three SPLs in which our cell and gene therapy clients will use our 'Flow Electroporation' technology and 'ExPERT' platform to further their pre-clinical and clinical programmes.
"As we continue to expand our SPL portfolio this year, we remain confident in our ability to support our current and prospective clients as new waves of next-generation cell therapies come to market."
At 0809 GMT, shares in MaxCyte were down 4.05% at 355p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
